標(biāo)題: Titlebook: Biosimilars; A New Generation of Jean-Louis Prugnaud,Jean-Hugues Trouvin Book 2013 Springer-Verlag France 2013 Biomedicine.Biosimilars.Cos [打印本頁] 作者: vitamin-D 時間: 2025-3-21 17:14
書目名稱Biosimilars影響因子(影響力)
書目名稱Biosimilars影響因子(影響力)學(xué)科排名
書目名稱Biosimilars網(wǎng)絡(luò)公開度
書目名稱Biosimilars網(wǎng)絡(luò)公開度學(xué)科排名
書目名稱Biosimilars被引頻次
書目名稱Biosimilars被引頻次學(xué)科排名
書目名稱Biosimilars年度引用
書目名稱Biosimilars年度引用學(xué)科排名
書目名稱Biosimilars讀者反饋
書目名稱Biosimilars讀者反饋學(xué)科排名
作者: phase-2-enzyme 時間: 2025-3-21 21:41
Book 2013 other issues, such as cost management and international nomenclature..?.This book is primarily intended for hospital-based physicians and pharmacists. It will also be a valuable resource for all actors from all countries who want to better understand the emergence of these new medicinal products wi作者: WATER 時間: 2025-3-22 03:06
,Biologicals’ Characteristics,his complexity’s consequence resides in the analytical techniques for the study of various structural aspects of the molecule population of interest. Powerful physico-chemical and biological methods have to be used in order to globally apprehend the molecules tridimensional integrity and ensure a th作者: BLA 時間: 2025-3-22 06:49
From the Biosimilar Concept to the Marketing Authorisation,adequate to evidence a biosimilar’s quality, safety and efficacy, due to the complexity of the products themselves but also of their production processes. The registration of biological products’ copies has been made possible by the creation of a specific regulatory framework by European regulatory 作者: 鞭子 時間: 2025-3-22 09:07
Immunogenicity,ors influencing immunogenicity—structural, linked to impurities and other production contaminants, factors linked to the medicine’s formulation, or linked to patients and treatment dependant—are studied in that chapter, as well as their consequences in regulatory terms.作者: micturition 時間: 2025-3-22 12:59
Substitution and Interchangeability,n of biosimilars is centralised as for reference products, the issue of substitution remains the specific field of the European Community Member States. In this chapter is described the French regulatory position—that does not allow the substitution of a reference biological product by a biosimilar,作者: Fatten 時間: 2025-3-22 19:46 作者: Mutter 時間: 2025-3-22 23:55 作者: alleviate 時間: 2025-3-23 02:11
Wouter van Toll,Arjan Egges,Jeroen D. Fokkerarket in value), payers’ (significant savings expected for all parties), at last doctors and pharmacists’. How costs are established, what savings may be expected, is there a liability specific to biosimilars? In this chapter, a quick comparative view of European and American approaches and the concept of interchangeability.作者: 記憶法 時間: 2025-3-23 08:36
Jean-Louis Prugnaud,Jean-Hugues TrouvinAnalysis of the complete legal and regulatory framework.Approach of the context of copies of biology and biotechnology drugs.Details the registration conditions.Analysis of these drugs’ marketing (dru作者: 太空 時間: 2025-3-23 09:46
http://image.papertrans.cn/b/image/188567.jpg作者: 修改 時間: 2025-3-23 17:45
Jen Rinaldi,Andrea LaMarre,Carla Ricehis complexity’s consequence resides in the analytical techniques for the study of various structural aspects of the molecule population of interest. Powerful physico-chemical and biological methods have to be used in order to globally apprehend the molecules tridimensional integrity and ensure a th作者: PACT 時間: 2025-3-23 19:31
https://doi.org/10.1007/978-1-4842-5482-0adequate to evidence a biosimilar’s quality, safety and efficacy, due to the complexity of the products themselves but also of their production processes. The registration of biological products’ copies has been made possible by the creation of a specific regulatory framework by European regulatory 作者: Nonporous 時間: 2025-3-24 00:19 作者: 龍蝦 時間: 2025-3-24 02:52 作者: 不妥協(xié) 時間: 2025-3-24 10:22 作者: FILLY 時間: 2025-3-24 12:59 作者: jaunty 時間: 2025-3-24 15:59 作者: concubine 時間: 2025-3-24 21:52
Immunogenicity,ors influencing immunogenicity—structural, linked to impurities and other production contaminants, factors linked to the medicine’s formulation, or linked to patients and treatment dependant—are studied in that chapter, as well as their consequences in regulatory terms.作者: declamation 時間: 2025-3-24 23:26
Biosimilars: Challenges Raised by Biosimilars: Who is Responsible for Cost and Risk Management?,arket in value), payers’ (significant savings expected for all parties), at last doctors and pharmacists’. How costs are established, what savings may be expected, is there a liability specific to biosimilars? In this chapter, a quick comparative view of European and American approaches and the concept of interchangeability.作者: legacy 時間: 2025-3-25 05:14
Learning Business English in ChinaConditions under which G-CSF biosimilars have been authorised for patients’ treatment: conducted studies, recommendations of the European Medicines Agency, indications authorised comparatively to the reference product. In the same way are detailed the conditions of prescription and interchangeability for that type of medicines.作者: STANT 時間: 2025-3-25 09:24 作者: Absenteeism 時間: 2025-3-25 14:11
,G-CSFs: Onco-Hematologist’s Point of View,Conditions under which G-CSF biosimilars have been authorised for patients’ treatment: conducted studies, recommendations of the European Medicines Agency, indications authorised comparatively to the reference product. In the same way are detailed the conditions of prescription and interchangeability for that type of medicines.作者: 莎草 時間: 2025-3-25 16:06
,The Oncologist’s Point of View,EPO’s biosimilars in oncology. After a reminder on general conditions for prescribing EPOs and international recommendations, the more specific prescription of biosimilars, their interchangeability, guidelines, traceability, are considered.作者: Fester 時間: 2025-3-25 23:26 作者: 熱心助人 時間: 2025-3-26 03:42
Book 2013prices. As patents expire, copies and price competition are expected throughout the world. However, due to the intrinsic heterogeneity and molecular complexity of biologic medicinal products, their copies cannot simply be authorized under the “generic rule” valid for small chemical entities..?.In re作者: impale 時間: 2025-3-26 05:15
istration conditions.Analysis of these drugs’ marketing (dru.Biologics have revolutionised the treatment of many severe conditions, delivering exceptional clinical results but also producing exceptionally high prices. As patents expire, copies and price competition are expected throughout the world.作者: 閑聊 時間: 2025-3-26 10:11 作者: ingrate 時間: 2025-3-26 14:36
Learning Business English in Chinahe conditions of biosimilars’ interchangeability compared to reference products’. Interchangeability is the result of a medical prescription processed by the various players of medical treatment and according to predefined recommendations.作者: 丑惡 時間: 2025-3-26 19:51
,Biologicals’ Characteristics,cess, an element of their characterisation. This process should be perfectly mastered in spite of variables inherent to the particular mode of expression of genetically engineered substances. In this chapter this complexity’s various elements are studied, with recombinant proteins taken as typical molecules.作者: 思想 時間: 2025-3-26 21:56 作者: amphibian 時間: 2025-3-27 05:05
https://doi.org/10.1007/978-1-4842-5482-0authorities, This framework is referred to as ??biosimilar approach??. In this chapter are described the general framework of registration and applications specific to onco-hematology field, through the examples of rG-CSF and EPO作者: 材料等 時間: 2025-3-27 07:06 作者: fledged 時間: 2025-3-27 10:55
Self-Assembly in Mobile and Modular Robotsdings, and explain why I decided to draw on and amend the work of Richard Florida to analyze and illuminate these findings. I also note that Florida himself conducted his initial research on the creative class within the City of Pittsburgh. I conclude by building on Florida’s brief commentary on con作者: intuition 時間: 2025-3-27 14:46 作者: 殘廢的火焰 時間: 2025-3-27 19:33
Exploring the Engineering Education Literature: Trends, Networks, and Themes Through Bibliometric Ical theories. As this area develops over time, it is increasingly necessary to study its dynamic research landscape to understand current trends, challenges, and opportunities. This paper addresses this need through a comprehensive bibliometric analysis of engineering education-related publications,
